ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years

May 9, 2014

Protocols Approved By NCI

April 30, 2004

In Brief: James Downing named CEO of St. Jude

June 27, 2014

Court Filing By Fisher; Board, Attacks Interim NSABP Leadership

August 12, 1994

Centers Subcommittee Kills Guidelines Proposal, Suggest Formula Ceiling On Core Grants

January 6, 1978

Commercial Firms Get Foot In The Door With CREG, But Won’t Be Permitted To Make Money On Grants

January 10, 1975